Teleflex Incorporated (BVMF:T1FX34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 32.90B +11.3% |
| Revenue (ttm) | 11.68B +158.8% |
| Net Income | 1.58B |
| EPS | 3.87 |
| Shares Out | n/a |
| PE Ratio | 16.05 |
| Forward PE | 15.65 |
| Dividend | 0.48 (0.78%) |
| Ex-Dividend Date | Nov 13, 2026 |
| Volume | n/a |
| Open | 62.04 |
| Previous Close | 62.04 |
| Day's Range | 62.04 - 62.04 |
| 52-Week Range | 52.65 - 74.99 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Teleflex
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and col... [Read more]
News
Teleflex price target raised to $170 from $165 at BofA
BofA analyst Travis Steed raised the firm’s price target on Teleflex (TFX) to $170 from $165 and keeps a Buy rating on the shares. Medical technology investor sentiment is “slightly…
Teleflex price target raised to $167 from $142 at Truist
Truist raised the firm’s price target on Teleflex (TFX) to $167 from $142 and keeps a Hold rating on the shares. The company delivered small top-line upside as the management…
Teleflex price target raised to $165 from $158 at BofA
BofA analyst Travis Steed raised the firm’s price target on Teleflex (TFX) to $165 from $158 and keeps a Buy rating on the shares. The firm views the company’s Q3…
Teleflex price target raised to $165 from $155 at Raymond James
Raymond James raised the firm’s price target on Teleflex (TFX) to $165 from $155 and keeps an Outperform rating on the shares. Teleflex delivered encouraging results with modest revenue upside…
Teleflex price target raised to $160 from $140 at Mizuho
Mizuho raised the firm’s price target on Teleflex (TFX) to $160 from $140 and keeps a Neutral rating on the shares.
Teleflex price target raised to $175 from $155 at RBC Capital
RBC Capital raised the firm’s price target on Teleflex (TFX) to $175 from $155 and keeps an Outperform rating on the shares.
Teleflex Earnings Call Transcript: Q3 2026
Q3 revenue grew 3.0% on an adjusted constant-currency basis, and adjusted EPS rose 39.2% to $2.63; FY26 EPS guidance increased to $7.50-$7.75. Integration progress and divestiture execution remain central to the 2027 margin and earnings step-up.
Teleflex Earnings release: Q3 2026
Teleflex released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Teleflex Slides: Q3 2026
Teleflex has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Teleflex Quarterly report: Q3 2026
Teleflex has published its Q3 2026 quarterly earnings report on November 5, 2026.
Teleflex reports Q3 adjusted EPS $2.63, consensus $1.89
Reports Q3 revenue $567.8M, consensus $565.36M. “We are pleased with our third quarter performance, which included margin expansion and robust earnings per share growth, even when excluding IEEPA tari...
Teleflex raises 2026 adjusted EPS view to $7.50-$7.75 from $6.90-$7.20
2026 EPS consensus $7.08. Lowers 2026 revenue growth view to 13.2%-14.2% from 13.4%-14.4% from 2025 revenue of $1.98B, consensus $2.27B.
Teleflex Announces Quarterly Dividend
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. Th...
Teleflex Reports Third Quarter Financial Results and Full Year 2026 Outlook
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 30, 2026. Third quarter 2026 continuing operation...
Teleflex announces FDA Breakthrough Device Designation for Freesolve RMS
Teleflex (TFX) announced that the U.S. FDA has granted Breakthrough Device Designation for its Freesolve Resorbable Magnesium Scaffold for percutaneous coronary intervention. To qualify for a BDD, dev...
Teleflex Announces FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthr...
Teleflex Announces Third Quarter 2026 Earnings Conference Call Information
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on ...
Teleflex price target lowered to $142 from $150 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Teleflex (TFX) to $142 from $150 and keeps a Hold rating on the shares as part of a broader research…
Teleflex price target lowered to $140 from $145 at Mizuho
Mizuho lowered the firm’s price target on Teleflex (TFX) to $140 from $145 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical devices and…
Teleflex completes patient enrollment in BIOMAG-LL Clinical Study
Teleflex (TFX) Iannounced the successful completion of patient enrollment in the BIOMAG-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve Resorbable Magnesium Scaffold...
Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG™-LL Cli...
Teleflex’s Arrowg+ard Technology reduces CLABSI risk in peer-reviewed study
Teleflex (TFX) announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters, or CVCs, protected with Arrowg+ard ...
Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Jou...
BofA upgrades Teleflex to Buy, says growth potential not appreciated
As previously reported, BofA analyst Travis Steed upgraded Teleflex (TFX) to Buy from Neutral with a price target of $158, up from $145. With a new management team and better…
Teleflex upgraded to Buy from Neutral at BofA
BofA upgraded Teleflex (TFX) to Buy from Neutral with a price target of $158, up from $145.